{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:42:27Z","timestamp":1794685347237,"version":"4.9.1"},"publisher-location":"Cham","reference-count":89,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030783105","type":"print"},{"value":"9783030783112","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-78311-2_6","type":"book-chapter","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T09:55:25Z","timestamp":1633859725000},"page":"97-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CML Chapter"],"prefix":"10.1007","author":[{"given":"David","family":"Snyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,10]]},"reference":[{"issue":"10","key":"6_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10):917\u2013927","journal-title":"N Engl J Med"},{"issue":"1","key":"6_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","volume":"17","author":"S Soverini","year":"2018","unstructured":"Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G (2018) Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer 17(1):49","journal-title":"Mol Cancer"},{"key":"6_CR3","doi-asserted-by":"crossref","unstructured":"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R et al (2018) Chronic myeloid leukemia, Version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Comprehensive Cancer Netw 16(9):1108\u20131135","DOI":"10.6004\/jnccn.2018.0071"},{"issue":"2","key":"6_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/ajh.10456","volume":"75","author":"DS Snyder","year":"2004","unstructured":"Snyder DS, McMahon R, Cohen SR, Slovak ML (2004) Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory. Am J Hematol 75(2):92\u201395","journal-title":"Am J Hematol"},{"issue":"3","key":"6_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","volume":"22","author":"NC Cross","year":"2009","unstructured":"Cross NC (2009) Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3):355\u2013365","journal-title":"Best Pract Res Clin Haematol"},{"issue":"11","key":"6_CR6","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","volume":"20","author":"S Branford","year":"2006","unstructured":"Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J et al (2006) Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 20(11):1925\u20131930","journal-title":"Leukemia"},{"issue":"9","key":"6_CR7","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26(9):2096\u20132102","journal-title":"Leukemia"},{"issue":"3","key":"6_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al (2012) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30(3):232\u2013238","journal-title":"J Clin Oncol"},{"issue":"11","key":"6_CR9","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3324\/haematol.2013.090282","volume":"98","author":"A Nazha","year":"2013","unstructured":"Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A et al (2013) Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 98(11):1686\u20131688","journal-title":"Haematologica"},{"issue":"10","key":"6_CR10","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/leu.2014.153","volume":"28","author":"B Hanfstein","year":"2014","unstructured":"Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C et al (2014) Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 28(10):1988\u20131992","journal-title":"Leukemia"},{"issue":"4","key":"6_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.23923","volume":"90","author":"N Iriyama","year":"2015","unstructured":"Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S et al (2015) Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol 90(4):282\u2013287","journal-title":"Am J Hematol"},{"issue":"4","key":"6_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63(4):789\u2013799","journal-title":"Blood"},{"issue":"11","key":"6_CR13","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 90(11):850\u2013858","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"6_CR14","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1182\/blood-2011-10-388967","volume":"119","author":"E Jabbour","year":"2012","unstructured":"Jabbour E, Cortes J, Nazha A, O\u2019Brien S, Quintas-Cardama A, Pierce S et al (2012) EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 119(19):4524\u20134526","journal-title":"Blood"},{"issue":"5","key":"6_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1179\/1607845412Y.0000000071","volume":"18","author":"B Uz","year":"2013","unstructured":"Uz B, Buyukasik Y, Atay H, Kelkitli E, Turgut M, Bektas O et al (2013) EUTOS CML prognostic scoring system predicts ELN-based \u2018event-free survival\u2019 better than Euro\/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology 18(5):247\u2013252","journal-title":"Hematology"},{"issue":"20","key":"6_CR16","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C et al (2016) Final 5-year study results of dasision: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 34(20):2333\u20132340","journal-title":"J Clin Oncol"},{"issue":"5","key":"6_CR17","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5):1044\u20131054","journal-title":"Leukemia"},{"issue":"3","key":"6_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW et al (2018) Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized bfore trial. J Clin Oncol 36(3):231\u2013237","journal-title":"J Clin Oncol"},{"issue":"19","key":"6_CR19","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L et al (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon and STI571 (IRIS). Blood 116(19):3758\u20133765","journal-title":"Blood"},{"issue":"23","key":"6_CR20","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408\u20132417","journal-title":"N Engl J Med"},{"issue":"12","key":"6_CR21","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG et al (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112(12):4437\u20134444","journal-title":"Blood"},{"issue":"6","key":"6_CR22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"issue":"11","key":"6_CR23","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029\u20131035","journal-title":"Lancet Oncol"},{"issue":"3","key":"6_CR24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A et al (2017) Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35(3):298\u2013305","journal-title":"J Clin Oncol"},{"issue":"5","key":"6_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B et al (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32(5):424\u2013430","journal-title":"J Clin Oncol"},{"issue":"5","key":"6_CR26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","volume":"144","author":"DM Ross","year":"2018","unstructured":"Ross DM, Masszi T, Gomez Casares MT, Hellmann A, Stentoft J, Conneally E et al (2018) Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol 144(5):945\u2013954","journal-title":"J Cancer Res Clin Oncol"},{"key":"6_CR27","doi-asserted-by":"crossref","unstructured":"Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K et al (2018) Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma, Myeloma Leukemia 18(5):353\u2013360 e1","DOI":"10.1016\/j.clml.2018.03.004"},{"key":"6_CR28","doi-asserted-by":"crossref","unstructured":"Rousselot P (2018) The story of tyrosine kinase inhibitors discontinuation in clinical practice. Leuk Lymphoma 1\u201310","DOI":"10.1080\/10428194.2018.1459611"},{"issue":"4","key":"6_CR29","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","volume":"19","author":"W Chan","year":"2011","unstructured":"Chan W, Wise S, Kaufman M, Ahn Y, Ensinger C, Haack T et al (2011) Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 19(4):556\u2013568","journal-title":"Cancer Cell"},{"key":"6_CR30","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MaS et al (2012) Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119(5):1123\u20131129","DOI":"10.1182\/blood-2011-08-376087"},{"issue":"12","key":"6_CR31","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/ajh.24536","volume":"91","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim D-W, Schafhausen P et al (2016) Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib. Am J Hematol 91(12):1206\u20131214","journal-title":"Am J Hematol"},{"issue":"1","key":"6_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2012.181","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG et al (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27(1):107\u2013112","journal-title":"Leukemia"},{"issue":"9","key":"6_CR33","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ajh.24423","volume":"91","author":"NP Shah","year":"2016","unstructured":"Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J et al (2016) Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 91(9):869\u2013874","journal-title":"Am J Hematol"},{"issue":"4","key":"6_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C et al (2018) Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132(4):393\u2013404","journal-title":"Blood"},{"issue":"1","key":"6_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O\u2019Brien S et al (2008) Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1):53\u201355","journal-title":"Blood"},{"issue":"9","key":"6_CR36","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3324\/haematol.11369","volume":"92","author":"FE Nicolini","year":"2007","unstructured":"Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M et al (2007) Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 92(9):1238\u20131241","journal-title":"Haematologica"},{"issue":"1","key":"6_CR37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3109\/10428194.2014.889826","volume":"56","author":"HJ Khoury","year":"2015","unstructured":"Khoury HJ, Cortes J, Baccarani M, Wetzler M, Masszi T, Digumarti R et al (2015) Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. Leuk Lymphoma 56(1):120\u2013127","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"6_CR38","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta B, Perrotti D (2004) The biology of CML blast crisis. Blood 103(11):4010\u20134022","journal-title":"Blood"},{"key":"6_CR39","first-page":"905","volume":"20","author":"G Specchia","year":"1996","unstructured":"Specchia G, Palumbo G, Pastore D, Mininni D, Mestice A, Liso V (1996) Extramedullary blast crisis in chronic myeloid leukemia. LeukRes. 20:905\u2013908","journal-title":"LeukRes."},{"key":"6_CR40","first-page":"1349","volume":"7","author":"A Urbano-Ispizua","year":"1993","unstructured":"Urbano-Ispizua A, Cervantes F, Matutes E, Villamor N, Pujades A, Sierra J et al (1993) Immunophenotypic characteristics of blast crisis of chronic myeloid leukaemia: correlations with clinico-biological features and survival. Leukemia 7:1349\u20131354","journal-title":"Leukemia"},{"issue":"7","key":"6_CR41","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1053\/hupa.2002.126190","volume":"33","author":"CC Ye","year":"2002","unstructured":"Ye CC, Echeverri C, Anderson JE, Smith JL, Glassman A, Gulley ML et al (2002) T-celL blast crisis of chronic myelogenous leukemia manifesting as a large mediastinal tumor. Hum Pathol 33(7):770\u2013773","journal-title":"Hum Pathol"},{"issue":"3\u20134","key":"6_CR42","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3109\/10428190009065845","volume":"39","author":"G Lucero","year":"2000","unstructured":"Lucero G, Birman V, Colimodio E, Bertinetti CM, Kotliar N, Murolo P et al (2000) Nodal T cell blast crisis in chronic myeloid leukemia. Leuk Lymphoma 39(3\u20134):435\u2013440","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"6_CR43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/cncr.28433","volume":"120","author":"P Strati","year":"2014","unstructured":"Strati P, Kantarjian H, Thomas D, O\u2019Brien S, Konoplev S, Jorgensen JL et al (2014) HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 120(3):373\u2013380","journal-title":"Cancer"},{"issue":"Suppl","key":"6_CR44","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.clml.2016.02.008","volume":"16","author":"J Radich","year":"2016","unstructured":"Radich J (2016) When to consider allogeneic transplantation in CML. Clin Lymphoma Myeloma Leuk 16(Suppl):S93\u2013S95","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"6_CR45","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann R (2012) How I treat CML blast crisis. Blood 120(4):737\u2013747","journal-title":"Blood"},{"issue":"1","key":"6_CR46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bbmt.2010.06.019","volume":"17","author":"A Boehm","year":"2011","unstructured":"Boehm A, Walcherberger B, Sperr WR, Wohrer S, Dieckmann K, Rosenmayr A et al (2011) Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant 17(1):133\u2013140","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"issue":"13","key":"6_CR47","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","volume":"117","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Cortes J, Santos FP, Jones D, O\u2019Brien S, Rondon G et al (2011) Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13):3641\u20133647","journal-title":"Blood"},{"issue":"6","key":"6_CR48","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/bmt.2011.194","volume":"47","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M et al (2012) Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 47(6):810\u2013816","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"6_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1179\/1607845413Y.0000000100","volume":"19","author":"SE Lee","year":"2014","unstructured":"Lee SE, Choi SY, Kim SH, Jang EJ, Bang JH, Byeun JY et al (2014) Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Hematology 19(2):63\u201372","journal-title":"Hematology"},{"issue":"15","key":"6_CR50","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1002\/cncr.30558","volume":"123","author":"FE Nicolini","year":"2017","unstructured":"Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF et al (2017) Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer 123(15):2875\u20132880","journal-title":"Cancer"},{"issue":"10","key":"6_CR51","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"S Saussele","year":"2010","unstructured":"Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML study IV. Blood 115(10):1880\u20131885","journal-title":"Blood"},{"issue":"17","key":"6_CR52","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1182\/blood-2012-02-409763","volume":"119","author":"E Warlick","year":"2012","unstructured":"Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M et al (2012) Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 119(17):4083\u20134090","journal-title":"Blood"},{"issue":"8","key":"6_CR53","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.bbmt.2015.04.005","volume":"21","author":"AP Nair","year":"2015","unstructured":"Nair AP, Barnett MJ, Broady RC, Hogge DE, Song KW, Toze CL et al (2015) Allogeneic hematopoietic stem cell transplantation is an effective salvage therapy for patients with chronic myeloid leukemia presenting with advanced disease or failing treatment with tyrosine kinase inhibitors. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant 21(8):1437\u20131444","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"issue":"2","key":"6_CR54","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.18632\/oncotarget.22979","volume":"9","author":"C Zheng","year":"2018","unstructured":"Zheng C, Zhu X, Tang B, Zhang X, Zhang L, Geng L et al (2018) Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells\/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood. Oncotarget 9(2):2848\u20132857","journal-title":"Oncotarget"},{"issue":"Suppl 1","key":"6_CR55","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1179\/102453312X13336169155853","volume":"17","author":"MC Pasquini","year":"2012","unstructured":"Pasquini MC (2012) Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. Hematology 17(Suppl 1):S79-82","journal-title":"Hematology"},{"issue":"1","key":"6_CR56","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/10428194.2014.910868","volume":"56","author":"JF Zeidner","year":"2015","unstructured":"Zeidner JF, Zahurak M, Rosner GL, Gocke CD, Jones RJ, Smith BD (2015) The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions? Leuk Lymphoma 56(1):128\u2013134","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6_CR57","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.clml.2013.09.010","volume":"14","author":"M Shanavas","year":"2014","unstructured":"Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J et al (2014) A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk 14(1):87\u201392","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"6_CR58","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.clml.2016.04.017","volume":"16","author":"Z DeFilipp","year":"2016","unstructured":"DeFilipp Z, Langston AA, Chen Z, Zhang C, Arellano ML, El Rassi F et al (2016) Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk philadelphia chromosome-positive leukemia? Clin Lymphoma Myeloma Leuk 16(8):466\u201371.e1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6_CR59","doi-asserted-by":"crossref","unstructured":"Chalandon Y, Iacobelli S, Hoek J, Koster L, Volin L, Finke J et al (2016) Use of first or second generation TKI for CML after allogeneic stem cell transplantation: a study by the CMWP of the EBMT. Blood 128(22):4685","DOI":"10.1182\/blood.V128.22.4685.4685"},{"issue":"1","key":"6_CR60","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.bbmt.2014.09.012","volume":"21","author":"DN Egan","year":"2015","unstructured":"Egan DN, Beppu L, Radich JP (2015) Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant 21(1):184\u2013189","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"issue":"12","key":"6_CR61","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.bbmt.2004.09.004","volume":"10","author":"P Anderlini","year":"2004","unstructured":"Anderlini P, Sheth S, Hicks K, Ippoliti C, Giralt S, Champlin RE (2004) Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant 10(12):883\u2013884","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"issue":"15","key":"6_CR62","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1158\/1078-0432.CCR-03-0580","volume":"10","author":"DJ DeAngelo","year":"2004","unstructured":"DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I et al (2004) Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 10(15):5065\u20135071","journal-title":"Clin Cancer Res"},{"issue":"30","key":"6_CR63","doi-asserted-by":"publisher","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","volume":"23","author":"G Hess","year":"2005","unstructured":"Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B et al (2005) Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 23(30):7583\u20137593","journal-title":"J Clin Oncol"},{"issue":"6","key":"6_CR64","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cncr.29141","volume":"121","author":"A Shimoni","year":"2015","unstructured":"Shimoni A, Volchek Y, Koren-Michowitz M, Varda-Bloom N, Somech R, Shem-Tov N et al (2015) Phase 1\/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121(6):863\u2013871","journal-title":"Cancer"},{"issue":"1","key":"6_CR65","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000228587","volume":"122","author":"E Klyuchnikov","year":"2009","unstructured":"Klyuchnikov E, Schafhausen P, Kroger N, Brummendorf TH, Osanmaz O, Asenova S et al (2009) Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol 122(1):6\u201310","journal-title":"Acta Haematol"},{"issue":"7","key":"6_CR66","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","volume":"109","author":"PA Carpenter","year":"2007","unstructured":"Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ et al (2007) Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109(7):2791\u20132793","journal-title":"Blood"},{"issue":"9","key":"6_CR67","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1182\/blood-2017-03-771121","volume":"130","author":"PA Carpenter","year":"2017","unstructured":"Carpenter PA, Johnston L, Fernandez HF, Radich JP, Mauro MJ, Flowers MED et al (2017) Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia. Blood 130(9):1170\u20131172","journal-title":"Blood"},{"issue":"13","key":"6_CR68","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","volume":"110","author":"E Olavarria","year":"2007","unstructured":"Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP et al (2007) Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 110(13):4614\u20134617","journal-title":"Blood"},{"issue":"5","key":"6_CR69","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.bbmt.2009.11.026","volume":"16","author":"MP Wright","year":"2010","unstructured":"Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL et al (2010) Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant 16(5):639\u2013646","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"issue":"3","key":"6_CR70","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bmt.1705554","volume":"39","author":"F Palandri","year":"2007","unstructured":"Palandri F, Amabile M, Rosti G, Bandini G, Benedetti F, Usala E et al (2007) Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Bone Marrow Transplant 39(3):189\u2013191","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"6_CR71","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s11899-018-0449-7","volume":"13","author":"JA Kennedy","year":"2018","unstructured":"Kennedy JA, Hobbs G (2018) Tyrosine kinase inhibitors in the treatment of chronic-phase cml: strategies for frontline decision-making. Curr Hematol Malig Rep 13(3):202\u2013211","journal-title":"Curr Hematol Malig Rep"},{"issue":"24","key":"6_CR72","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34(24):2851\u20132857","journal-title":"J Clin Oncol"},{"key":"6_CR73","doi-asserted-by":"crossref","unstructured":"Law AD, Dong Hwan Kim D, Lipton JH (2017) Pregnancy: part of life in chronic myelogenous leukemia. Leuk Lymphoma 58(2):280\u2013287","DOI":"10.1080\/10428194.2016.1201571"},{"issue":"12","key":"6_CR74","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.24186","volume":"90","author":"JE Cortes","year":"2015","unstructured":"Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF (2015) The impact of dasatinib on pregnancy outcomes. Am J Hematol 90(12):1111\u20131115","journal-title":"Am J Hematol"},{"issue":"9","key":"6_CR75","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1080\/15384101.2016.1160976","volume":"15","author":"D Moreno-Lorenzana","year":"2016","unstructured":"Moreno-Lorenzana D, Aviles-Vazquez S, Sandoval Esquivel MA, Alvarado-Moreno A, Ortiz-Navarrete V, Torres-Martinez H et al (2016) CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI. Cell Cycle (Georgetown, Tex). 15(9):1276\u20131287","journal-title":"Cell Cycle (Georgetown, Tex)."},{"issue":"5","key":"6_CR76","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","volume":"17","author":"B Zhang","year":"2010","unstructured":"Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD et al (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17(5):427\u2013442","journal-title":"Cancer Cell"},{"key":"6_CR77","doi-asserted-by":"crossref","unstructured":"Yokota A, Hirai H, Hayashi Y, Sato R, Adachi H, Sato F et al (2016) C\/EBP\u03b2 is a critical regulator of CML stem cell differentiation and exhaustion induced by interferon-\u03b1. Blood 128(22):1120","DOI":"10.1182\/blood.V128.22.1120.1120"},{"issue":"5","key":"6_CR78","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT, Heinrich L et al (2015) Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29(5):1123\u20131132","journal-title":"Leukemia"},{"issue":"4","key":"6_CR79","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nm.4499","volume":"24","author":"B Zhang","year":"2018","unstructured":"Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H et al (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24(4):450\u2013462","journal-title":"Nat Med"},{"issue":"12","key":"6_CR80","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/leu.2017.264","volume":"31","author":"W Qiang","year":"2017","unstructured":"Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P et al (2017) Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia 31(12):2844\u20132847","journal-title":"Leukemia"},{"issue":"10","key":"6_CR81","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1172\/JCI68951","volume":"123","author":"P Neviani","year":"2013","unstructured":"Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ et al (2013) PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Investig 123(10):4144\u20134157","journal-title":"J Clin Investig"},{"issue":"10","key":"6_CR82","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/leu.2013.151","volume":"27","author":"JG Harb","year":"2013","unstructured":"Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ et al (2013) Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia 27(10):1996\u20132005","journal-title":"Leukemia"},{"issue":"8","key":"6_CR83","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1182\/blood-2016-05-714089","volume":"129","author":"P Agarwal","year":"2017","unstructured":"Agarwal P, Zhang B, Ho Y, Cook A, Li L, Mikhail FM et al (2017) Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI. Blood 129(8):1008\u20131020","journal-title":"Blood"},{"issue":"23","key":"6_CR84","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","volume":"128","author":"B Zhang","year":"2016","unstructured":"Zhang B, Chu S, Agarwal P, Campbell VL, Hopcroft L, Jorgensen HG et al (2016) Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. Blood 128(23):2671\u20132682","journal-title":"Blood"},{"issue":"23","key":"6_CR85","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","volume":"128","author":"H Agerstam","year":"2016","unstructured":"Agerstam H, Hansen N, von Palffy S, Sanden C, Reckzeh K, Karlsson C et al (2016) IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood 128(23):2683\u20132693","journal-title":"Blood"},{"issue":"11","key":"6_CR86","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.7150\/thno.16139","volume":"6","author":"Y Jin","year":"2016","unstructured":"Jin Y, Yao Y, Chen L, Zhu X, Jin B, Shen Y et al (2016) Depletion of gamma-catenin by histone deacetylase inhibition confers elimination of CML stem cells in combination with imatinib. Theranostics. 6(11):1947\u20131962","journal-title":"Theranostics."},{"issue":"9","key":"6_CR87","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/cas.12216","volume":"104","author":"I Mizoguchi","year":"2013","unstructured":"Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi J, Tauchi T, Kimura Y et al (2013) Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci 104(9):1146\u20131153","journal-title":"Cancer Sci"},{"issue":"5","key":"6_CR88","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Stromberg U, Schlums H, Guilhot J, Bruck O, Lahteenmaki H et al (2017) Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31(5):1108\u20131116","journal-title":"Leukemia"},{"key":"6_CR89","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"T Hughes","year":"2019","unstructured":"Hughes T, Mauro M, Cortes J, Minami H, Rea D, DeAngelo D et al (2019) Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. NEJM 381:2315\u20132326","journal-title":"NEJM"}],"container-title":["Cancer Treatment and Research","Biology and Treatment of Leukemia and Bone Marrow Neoplasms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-78311-2_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T11:17:35Z","timestamp":1673435855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-78311-2_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030783105","9783030783112"],"references-count":89,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-78311-2_6","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-3-030-78311-2","asserted-by":"object"}]},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"10 October 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}